TGTX TG Therapeutics Inc.

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, being held in New York, NY on September 8 – 10, 2025. The fireside chat is scheduled to take place on Monday, September 8, 2025, at 10:30am ET.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at .

ABOUT TG THERAPEUTICS

TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) in Europe, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom, Swissmedic in Switzerland, and Australia’s Therapeutic Goods Administration (TGA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit , and follow us on X (formerly Twitter)  and on .

BRIUMVI® is a registered trademark of TG Therapeutics, Inc.

CONTACT:

Investor Relations

Email:

Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:

Email:

Telephone: 1.877.575.TGTX (8489), Option 6



EN
04/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TG Therapeutics Inc.

 PRESS RELEASE

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Glob...

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, being held in New York, NY on September 8 – 10, 2025. The fireside chat is scheduled to take place on Monday, September 8, 2025, at 10:30am ET. A live webcast of the fires...

 PRESS RELEASE

TG Therapeutics Announces Completion of Existing Share Repurchase Prog...

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase program, which was initially announced in August 2024. Under that program, the Company repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share. In addition, the Company’s Board of Directors has authorized a new share repurchase program to...

 PRESS RELEASE

TG Therapeutics to Participate in the Cantor Global Healthcare Confere...

TG Therapeutics to Participate in the Cantor Global Healthcare Conference Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare Conference, being held in New York, NY on September 3 - 5, 2025. The fireside chat is scheduled to take place on Wednesday, September 3, 2025, at 10:20am ET. A live webcast of the fireside chat will be available on the Even...

 PRESS RELEASE

TG Therapeutics Reports Second Quarter 2025 Financial Results and Rais...

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million Conference call to be held today, Monday, August 4, 2025, at 8:30 AM ET    NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the second quarter of 2025, along with recent company developments...

 PRESS RELEASE

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financi...

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update Conference Call to be Held Monday, August 4, 2025, at 8:30 am ET NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 4, 2025, at 8:30 AM ET to discuss results for the second quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch